Stopping and Starting Mounjaro: What Actually Happens

Step 1, Why people stop Mounjaro, and what the evidence says happens next

There are plenty of legitimate reasons to pause tirzepatide: side effects that need time to settle, surgery, pregnancy planning, cost, or simply reaching a weight that feels stable. Stopping is not a failure, and the medicine is not designed to be taken indefinitely by everyone.

What the evidence does make clear is that tirzepatide's effects are ongoing rather than permanent. The SURMOUNT-4 extension trial (published data cited in NICE's appraisal of tirzepatide (TA1026)) showed that participants who switched from tirzepatide to placebo after 36 weeks regained a significant portion of the weight they had lost, while those who continued the medicine maintained their results. This is consistent with what we understand about how GLP-1 and GIP receptor agonists work: they suppress appetite and slow gastric emptying while you take them, but those physiological effects wind down after the last dose.

That does not mean stopping is wrong. It means restarting (if your weight or health begins to drift back) is a valid and clinically supported option. The NHS tirzepatide medicines page notes that treatment is used alongside a reduced-calorie diet and increased physical activity, so the lifestyle elements you build during treatment matter a great deal to what happens after you stop.

If you are considering stopping because of a side effect rather than a lifestyle choice, it is worth speaking to your prescriber first. Dose reduction, rather than full cessation, sometimes resolves tolerability issues while keeping progress on track.

Step 2 (How the dose schedule works when you restart

Mounjaro is titrated) meaning the dose increases gradually over time, starting at 2.5 mg. That cautious escalation exists for a reason: it gives your digestive system time to adjust. When you stop and then restart after a meaningful gap, your tolerance to the medicine has reset to some degree, and jumping straight back to a higher dose risks a rough return of nausea, vomiting or other gastrointestinal symptoms.

General clinical guidance (and the approach our prescribers follow) is that a short break of one to two weeks may not require a dose step-down, especially if you were well-established on your dose and tolerating it well. A gap of four weeks or more usually calls for dropping back at least one step on the schedule (so, for example, restarting at 2.5 mg or 5 mg even if you had reached 10 mg). The prescriber will weigh up your individual history, any health changes during the break, and how you are currently feeling.

You can read more about the full process in our guide to how to start Mounjaro, which covers the titration schedule in detail. For specifics about restarting after a defined gap, our pages on restarting after a month and restarting after two weeks give more targeted guidance. The short version: do not simply resume where you left off without a prescriber confirming it is appropriate.

Cost is sometimes a factor in pauses. If that is part of your thinking, our Mounjaro cost page explains what a private prescription realistically involves and what is included in a clinically supervised service.

Step 3, The clinical review before you restart, and what it covers

At a regulated service, restarting is not just a matter of placing a new order. Before a prescriber approves a repeat prescription, they need to know that treatment is still appropriate for you now, not just that it was appropriate when you first started.

Relevant questions include: has your weight, BMI or health status changed during the break? Are the conditions that qualified you for treatment still present? Have you started any new medicines that could interact? For women, contraception matters too: tirzepatide can reduce the absorption of oral contraceptive pills, so NHS guidance recommends adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase. If your break was long enough that you are in effect restarting from 2.5 mg, that four-week window applies again.

At nume, the review before a restart follows exactly the same process as the original consultation. A GPhC-registered Independent Prescriber reads your answers, checks your current circumstances, and makes a clinical decision. You can meet our clinical team to understand who is involved in that review. If you have questions before you restart, our team is available seven days a week via the contact page.

For a broader overview of how tirzepatide works and what the treatment involves, the tirzepatide information page is a good starting point. If you have already stopped and are wondering whether starting again is right for you, our dedicated page on restarting Mounjaro after stopping covers that question directly.